CME Presentations

Pediatric Neuroblastoma - SIOP



  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Developmental Therapeutics Advanced Practice Nurse

    Jennifer Saggio, RN, MSN, CRNP, CPON, MSN, is a neuroblastoma nurse practitioner at The Children’s Hospital of Philadelphia (CHOP) in Pennsylvania, and has been a nurse practitioner in the Division of Oncology at CHOP for the past 18 years. Ms Saggio coordinates care for children with recurrent/refractory neuroblastoma, and provides consultations to physicians, nurses, and families in order to meet the complex needs of both hospitalized and ambulatory patients with neuroblastoma. Her team cares for patients who live in the Philadelphia region, those who travel from throughout the United States, and to a large population of international patients as well. She received her graduate degree from the Pediatric Acute/Chronic Care NP Program at the University of Pennsylvania in Philadelphia.
  • Giselle Saulnier Sholler, MD, MSc

    Giselle Saulnier Sholler, MD, MSc

    Giselle Saulnier Sholler, MD, MSc

    Professor of Pediatrics and Principal Investigator

    Giselle Sholler, MD, MSc, is the Director of the Isabella Santos Foundation Solid and Rare Tumor Program at Levine Children’s Hospital and founder and Chair of the Beat Childhood Cancer consortium. Also, she is currently an Associate Professor at Michigan State University College of Human Medicine.

    Dr. Sholler’s research focus has been on Precision Medicine approaches to cancer and studying difluoromethylornithine (DFMO) for children with neuroblastoma. Dr. Sholler’s laboratory has conducted research, which has led to the opening of 18 clinical trials with a focus on precision medicine for children with cancer. With the support of the Beat Childhood Cancer Foundation, and together with the FDA, Dr. Sholler is working to make this drug available to children everywhere.
  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.

CME Information

Global Logo PQH Logo
Through the Patient/Family Looking Glass: Perspectives in Treatment Planning by Disease Compartments for Pediatric Neuroblastoma
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in conjunction with the 2021 SIOP Virtual Conference.


This activity is supported by an educational grant from Y-mAbs Therapeutics, Inc.


This activity was released on October 29, 2021 and is valid for 12 months. Requests for credit must be made no later than October 29, 2022.


The educational design of this activity addresses the needs of pediatric oncology nurses, advanced practice providers (including nurse practitioners and physician assistants), pediatric oncologists, social workers, and other members of the team caring for children with pediatric neuroblastoma.


With an ever-improving understanding of clinical and biological risk factors, treatment strategies for pediatric neuroblastoma have become more tailored based on risk stratification, predicted response, and risk of relapse. However, it is also important to consider treatment by compartmentalizing neuroblastoma and planning in concordance with the perspectives and goals of patients and their families.

Join a panel of experts for an in-depth discussion of pediatric neuroblastoma and its treatment across the continuum of care, treatment of bone/bone-marrow and CNS/leptomeningeal metastases, and use of new and emerging prognostic and predictive markers. Experts will also discuss the need to integrate patient and family perspectives into treatment planning to improve outcomes and enhance treatment and side-effect monitoring.


After completing this activity, the participant should be better able to:
  • Integrate immunotherapeutic approaches for the management of pediatric neuroblastoma with bone and/or bone marrow involvement
  • Discuss minimal residual disease as a prognostic and predictive marker and implications for practice
  • Evaluate current and emerging treatment and monitoring strategies at diagnosis and relapse for patients with CNS/leptomeningeal metastases from neuroblastoma
  • Facilitate patient/family-centered strategies into treatment planning to optimize care and patient experience


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Navin Pinto, MD
Associate Professor of Pediatrics
Cancer & Blood Disorders Center
Seattle Children's Hospital
Nothing to disclose
Jennifer N. Saggio, MSN, CRNP
Advanced Practice Nurse Neuroblastoma Developmental Therapeutics
Center for Childhood Cancer Research and Division of Oncology
The Children's Hospital of Philadelphia
Nothing to disclose
Giselle Saulnier Sholler, MD, MSc
Professor of Pediatrics and Principal Investigator
Sholler Pediatric Oncology Research Laboratory
Director, Isabella Santos Foundation Rare and Solid Tumor Program
Levine Children’s Hospital
Scientific Advisory Committee: Y-Mabs Therapeutics

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Rhys Williams, RN, MSN, FNP Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Kim Rodriguez Nothing to disclose
Carole Drexel Nothing to disclose
Jaimee Harris-Gold Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at